Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Histology classification challenges for the endoscopic treatment of early gastric cancer

  • 113 Accesses

  • 1 Citations

This is a preview of subscription content, log in to check access.

References

  1. 1.

    Kim HM, Pak KH, Chung MJ, Cho JH, Hyung WJ, Noh SH, Kim CB, Lee YC, Song SY, Lee SK (2011) Early gastric cancer of signet ring cell carcinoma is more amenable to endoscopic treatment than is early gastric cancer of poorly differentiated tubular adenocarcinoma in select tumor conditions. Surg Endosc 25:3087–3093

  2. 2.

    Katsios GC, Baltogiannis G, Roukos DH (2010) Laparoscopic surgery for gastric cancer: comparative-effectiveness research and future trends. Expert Rev Anticancer Ther 10:473–476

  3. 3.

    Liakakos T, Roukos D (2008) Laparoscopic gastrectomy: advances enable wide clinical application. Surg Endosc 22:1553–1555

  4. 4.

    Liakakos T, Roukos DH (2009) Randomized evidence for laparoscopic gastrectomy short-term quality of life improvement and challenges for improving long-term outcomes. Ann Surg 250:349–350

  5. 5.

    Roukos DH (2009) Laparoscopic gastrectomy and personal genomics: high-volume surgeons and predictive biomedicine may govern the future for resectable gastric cancer. Ann Surg 250:650–651

  6. 6.

    Liakakos T, Roukos DH (2008) Is there any long-term benefit in quality of life after laparoscopy-assisted distal gastrectomy for gastric cancer? Surg Endosc 22:1402–1404

  7. 7.

    Ziogas D, Polychronidis A, Kanellos I, Roukos D (2009) Laparoscopic colectomy survival benefit for colon cancer: is evidence from a randomized trial true? Ann Surg 249:695–696

  8. 8.

    Ziogas D, Roukos D (2008) Robotic surgery for rectal cancer: may it improve also survival? Surg Endosc 22:1405–1406

  9. 9.

    Nikiteas N, Roukos D, Kouraklis G (2011) Robotic versus laparoscopic surgery: perspectives for tailoring an optimal surgical option. Expert Rev Med Devices 8:295–298

  10. 10.

    Roukos DH (2011) Trastuzumab and beyond: sequencing cancer genomes and predicting molecular networks. Pharmacogenomics J 11:81–92

  11. 11.

    Roukos DH (2010) Next-generation sequencing and epigenome technologies: potential medical applications. Expert Rev Med Devices 7:723–726

  12. 12.

    Roukos DH (2010) Complete genome sequencing and network modeling to overcome trastuzumab resistance. Pharmacogenomics 11:1039–1043

  13. 13.

    Roukos DH (2010) Next-generation, genome sequencing-based biomarkers: concerns and challenges for medical practice. Biomark Med 4:583–586

  14. 14.

    Katsios C, Roukos DH (2010) Individual genomes and personalized medicine: life diversity and complexity. Per Med 7:347–350

  15. 15.

    Roukos DH, Katsios C, Liakakos T (2010) Genotype-phenotype map and molecular networks: a promising solution in overcoming colorectal cancer resistance to targeted treatment. Expert Rev Mol Diagn 10:541–545

  16. 16.

    Roukos DH, Ziogas D (2010) From tumor size and HER2 status to systems oncology for very early breast cancer treatment. Expert Rev Anticancer Ther 10(2):123–128

  17. 17.

    Roukos DH (2009) Personal genomics and genome-wide association studies: novel discoveries but limitations for practical personalized medicine. Ann Surg Oncol 16(3):772–773

  18. 18.

    Roukos DH (2010) Bionetworks-based personalized medicine versus comparative-effectiveness research or harmonization of both in cancer management? Expert Rev Mol Diagn 10(3):247–250

  19. 19.

    Roukos DH (2011) Cancer genome explosion and systems biology: impact on surgical oncology? Ann Surg Oncol 18(1):12–15

  20. 20.

    Roukos DH, Kappas AM (2002) Targeting the optimal extent of lymph node dissection for gastric cancer. J Surg Oncol 81:59–62

  21. 21.

    Roukos DH, Paraschou P, Lorenz M (2000) Distal gastric cancer and extensive surgery: a new evaluation method based on the study of the status of residual lymph nodes after limited surgery. Ann Surg Oncol 7(10):719–726

  22. 22.

    Roukos DH, Agnanti NJ, Paraskevaidis E, Kappas AM (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers of BRCA1 or BRCA2 mutations. Ann Surg Oncol 9(10):941–943

  23. 23.

    Roukos DH (2009) Genome-wide association studies and aggressive surgery toward individualized prevention, and improved local control and overall survival for gastric cancer. Ann Surg Oncol 16(4):795–798

  24. 24.

    Liakakos T, Roukos DH (2008) More controversy than ever - challenges and promises towards personalized treatment of gastric cancer. Ann Surg Oncol 15(4):956–960

  25. 25.

    Roukos DH (2009) Breast cancer outcomes: the crucial role of the breast surgeon in the era of personal genetics and systems biology. Ann Surg 249(6):1067–1068

  26. 26.

    Briasoulis E, Fatouros M, Roukos DH (2007) Level I evidence in support of perioperative chemotherapy for operable gastric cancer: sufficient for wide clinical use? Ann Surg Oncol 14:2691–2695

  27. 27.

    Roukos DH (2000) Extended (D2) lymph node dissection for gastric cancer: do patients benefit? Ann Surg Oncol 7:253–255

  28. 28.

    Roukos DH (2011) “Big” science: genome regulatory networks and novel molecular tools to improve health. Expert Rev Mol Diagn 11(2):123–126

  29. 29.

    Roukos DH (2011) Measurable evidence of miRNAs as regulators of cancer networks and therapeutic targets. Expert Rev Med Devices 8(2):123–126

  30. 30.

    Roukos DH (2011) Chromatin: a key player in complex gene regulation and future cancer therapeutics. Epigenomics 3(4):395–399

  31. 31.

    Roukos DH (2011) Networks medicine: from reductionism to evidence of complex dynamic biomolecular interactions. Pharmacogenomics 12(5):695–698

Download references

Disclosure

Christof Hottenrott has no conflicts of interest or financial ties to disclose.

Author information

Correspondence to Christof Hottenrott.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Hottenrott, C. Histology classification challenges for the endoscopic treatment of early gastric cancer. Surg Endosc 26, 2092–2093 (2012). https://doi.org/10.1007/s00464-011-2134-y

Download citation

Keywords

  • Gastric Cancer
  • Endoscopic Submucosal Dissection
  • Early Gastric Cancer
  • Endoscopic Mucosal Resection
  • Lymphovascular Invasion